Dr. Jeroen Aerssens joined Rejuvenate Biomed as Chief Development Officer. In this role, he oversees all aspects of clinical research and development in the company, including compound development strategy, clinical trial design and execution, and collaborations with stakeholders. Jeroen brings over 25 years of experience in pharmaceutical R&D, encompassing preclinical drug discovery, translational research and clinical development. He is particularly recognized for his expertise in biomarkers and clinical translational science. Before joining Rejuvenate Biomed, Dr. Aerssens held senior scientific leadership positions at Johnson & Johnson companies, including Janssen Pharmaceutica and Tibotec, where he built and managed research teams across various divisions. Jeroen contributed to the clinical development programs of several market-approved drugs, such as galantamine and simeprevir.  Apart from his work in the pharmaceutical industry, he also had a successful academic career at the universities of Leuven (postdoc) and Maastricht (assistant professor). Throughout his career, Jeroen maintained a strong interest in patient-oriented research aimed at addressing knowledge gaps at the molecular level. He co-invented over 20 patent applications and co-authored more than 130 peer-reviewed publications, making significant scientific contributions to a diverse range of diseases, including infectious diseases, bone disorders, metabolic syndrome, gastroenterology, neuroscience, and oncology. Dr. Aerssens holds a PhD in Medical Sciences and a master’s degree in Bioengineering from Leuven University, and a certificate in Health Economics from EHSAL Management School (Belgium).